AptarGroup is a global leader in the design and manufacturing of drug and consumer product dosing, dispensing and protection technologies, serving diversified end markets including pharmaceutical, fragrance, facial skincare, color cosmetics, food, beverage, personal care and home care. The company has approximately 14,000 employees in approximately 20 different countries and has manufacturing facilities located throughout the world including North America, Europe, Asia and Latin America. Consumers' and patients' preferences for convenience and product differentiation through drug delivery and packaging design and function have driven a continued shift from non-dispensing formats to dispensing systems that offer enhanced shelf appeal, ease of use, convenience, cleanliness and accuracy of dosage. The industry is highly competitive, with competition based on brand recognition, product quality, price, and innovation, and competitors include privately and publicly held entities that range from regional to international companies.
Aptar has approximately 5,000 customers with no single customer or group of affiliated customers accounting for greater than 4% of 2025 Net Sales. The company believes its competitive advantages include consistent high levels of innovation, quality, regulatory, pharma services, geographic diversity, financial strength and reliability and breadth of products and services. Manufacturing strength lies in the ability to mold complex plastic components and formulate and finish elastomer and silicone components in a cost-effective manner and to assemble products at high speeds. The company faces meaningful competition from local and regional competitors and has experienced some competition in Europe, Latin America and the United States from low cost Asian suppliers, particularly in the beauty and personal care market.
Aptar generates revenue through the design and manufacturing of drug delivery, consumer product dispensing, active material science solutions and services for the pharmaceutical, fragrance and facial skincare, personal care, home care, food and beverage markets. The company's primary products are dispensing pumps, closures, aerosol valves, elastomeric primary packaging components, active material science solutions and digital health solutions. Revenue is recognized when performance obligations are satisfied, typically upon shipment or delivery of goods, and the majority of revenues are derived from product, tooling and service contract sales, with additional revenues from license, exclusivity and royalty arrangements.
The Pharma segment is the largest segment in terms of net sales and total assets, representing approximately 46% and 43% of Net Sales and Total Assets, respectively, for 2025 and accounted for 69% of Adjusted EBITDA excluding non-allocated corporate costs. The segment sells proprietary dispensing systems, drug delivery systems, sealing solutions, pharma packaging and services to the prescription drug, consumer health care, injectables, active material science solutions and digital health markets. Sales to the prescription drug and digital health markets accounted for approximately 51% of the segment's total net sales in 2025, sales to the consumer health care market accounted for approximately 20%, sales to the injectables market accounted for approximately 19%, and sales of active material science solutions products accounted for approximately 10%.
The Beauty segment is the second largest segment in terms of net sales and total assets, representing 35% and 32% of Net Sales and Total Assets, respectively, for 2025 and accounted for 18% of Adjusted EBITDA excluding non-allocated corporate costs. The segment sells a broad variety of pumps, airless systems and valves to the fragrance, color cosmetics, facial skincare, personal care and home care markets. Sales to the fragrance, facial skincare, and color cosmetics markets accounted for approximately 58% of the segment's total net sales in 2025, sales to the personal care market accounted for approximately 37%, and sales to the home care market accounted for approximately 5%. The Closures segment accounted for 19% and 15% of Net Sales and Total Assets, respectively, for 2025 and accounted for 13% of Adjusted EBITDA excluding non-allocated corporate costs. Sales to the food market accounted for approximately 49% of the segment's total net sales in 2025, sales to the beverage market accounted for approximately 26%, sales to the personal care market accounted for approximately 17%, and sales to the beauty, home care and other markets accounted for approximately 8%.
During 2025 and 2024, the company acquired and invested in several companies to strengthen and broaden its portfolio. In December 2025, Aptar acquired 100% of the equity interests in Sommaplast for $27.0 million 1 (net of $0.7 million 2 cash acquired), which was funded with cash on hand with a portion held in escrow, and a contingent consideration liability of $4.0 million 3 is the accounting valuation due to sellers related to earn-out. In July 2025, Aptar executed its call option to increase its beneficial ownership to 80% in three related companies collectively referred to as "BTY" for approximately $29.0 million 4. In October 2024, Aptar acquired 40% of the equity interests in Ningbo Jinyu Technology Industry Co., Ltd., doing business as Goldrain, for approximately $99.0 million 5. On October 10, 2024, a share purchase authorization of up to $500.0 million 6 of common stock was authorized. During the fourth quarter of 2025, the company repurchased approximately 1.5 million 7 shares for approximately $175.0 million 8. Subsequent to year end, the 2024 share authorization was superseded on February 3, 2026, when the Board approved a new share repurchase authorization of up to $600.0 million 9 of common stock. During 2025, the company paid $120.8 million 10 in dividends to stockholders.
Reported sales increased 5% and core sales increased 2% in 2025. Reported net income increased 5% to $392.8 million 11 and reported earnings per share increased 7% to $5.89 12. The company returned $485.8 million 13 to shareholders through share repurchases and dividends. Capital expenditures decreased year over year, ending the year at about 7% of sales. 2025 was the 32nd consecutive year of paying an annually increasing dividend.
Aptar expects earnings per share for the first quarter of 2026, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition-related costs, to be in the range of $1.13 to $1.21 14 and this guidance is based on an effective tax rate range of 21% to 23% 15.
The company's strategy is focused on strengthening its position as a global provider in drug and consumer dosing, dispensing and protection technologies while delivering long-term value through strategic focus and execution. Aptar seeks profitable organic growth by leveraging capabilities, assets, capacity and by sharing technologies across segments, with an added focus in high growth regions. The company aims to maximize return on investments while focusing on the top and bottom lines. Acquisitions and partnerships are evaluated to help expand technology platforms, geographic reach and product offerings, subject to strategic fit and financial discipline.
Aptar emphasizes three pillars of functional excellence designed to ensure performance at high levels in core manufacturing and commercial functions: "innovate," "produce" and "sell." The company continues to invest in product platforms designed to improve sustainability, including enhanced recyclability of pharmaceutical delivery systems. The company has launched products and components in North America, Europe, Latin America and Asia made with post-consumer recycled resin and continues to explore additional opportunities for alternative resins and recyclable products. New product offerings include Purity Lite, a mono-material, lightweight, fully-recyclable closure; SimpliCycle, an award winning recyclable valve; Rocket, a sports cap awarded Best in Cap at the 17th Global Water Drinks Congress in 2020; Future, a mono-material, fully-recyclable pump; APF Futurity, a highly recyclable nasal spray pump; Mono Micro, a mono-material and fully recyclable airless dispenser; and GSA Advance and PZ Advance full plastic recyclable pumps.
The company seeks to manage selling, research & development and administrative costs and overall fixed costs by leveraging Global Business Service Centers. These initiatives are intended to support a more efficient and scalable operating structure while improving return on invested capital. The company continues to streamline and reduce its fixed costs in order to increase operating efficiencies. For the years ended December 31, 2025 and 2024, the company recognized $9.8 million 16 and $13.0 million 17, respectively, of restructuring costs related to its initiative to better leverage its fixed cost base through growth and cost reduction measures. The cumulative expense incurred as of December 31, 2025 was $74.5 million 18.
In 2026, the company expects its capital investments to be in the range of $260.0 million to $280.0 million 19. The company expects to have financing cash outlays of approximately $156.5 million 20 to fund short and long term debt obligations in 2026, which are expected to be covered by cash on hand or additional borrowings on the revolving credit facility. Based on the current business plan, management believes that 2026 operating cash flow will be more than sufficient to fund working capital needs, capital investments in the business and outstanding purchase commitments.
During 2025, the company spent $270.4 million 21 on capital expenditures, $60.2 million 22 on acquisitions, net of cash acquired and $6.3 million 23, net for investments in equity securities. The company paid $120.8 million 24 of dividends, purchased $365.0 million 25 of its common stock that was placed into treasury stock, received $600.2 million 26 in proceeds from long-term debt obligations, primarily from its note issuance, repaid $166.6 million 27 of long-term debt primarily related to private placement notes and received proceeds of $18.9 million 28 on stock option exercises. On November 20, 2025, the company issued $600.0 million 29 in aggregate principal amount of 4.75% Senior Notes due March 2031 in an underwritten public offering. On December 16, 2025, the company repaid in full the $125.0 million 30 3.6% Senior Notes that were due in December 2025.
Geopolitical conditions, including trade disputes and acts of war or terrorism, could have a material adverse effect on operations and financial results. In 2025, the U.S. government imposed a series of additional substantial tariffs on a broad range of imports from various countries, including China, Canada and Mexico, and in response, several countries have imposed or announced counter measures. Such tariffs and countermeasures have increased the cost of certain raw materials and components used in packaging solutions, and have the potential to disrupt the global supply chain and create additional operational challenges. The continued invasion of Ukraine by Russia has not had a material direct impact to consolidated results, but the company has experienced indirect impacts including higher energy and other input costs as well as certain supply chain disruptions.
The company faces foreign currency translation and transaction risks, with primary foreign exchange exposure to the euro, but also exposure to the Chinese yuan, Brazilian real, Argentine peso, Mexican peso, Swiss franc and other Asian, European and Latin American currencies. A strengthening U.S. dollar has a dilutive effect on financial statements, while a weakening U.S. dollar relative to foreign currencies has an additive translation effect. The company manages exposures to foreign exchange principally with forward exchange contracts to economically hedge recorded transactions and firm purchase and sales commitments denominated in foreign currencies. The average U.S. dollar exchange rate weakened compared to the euro and most other major European currencies in which the company operates, resulting in a 2% positive currency translation impact during 2025.
Management's message emphasizes that 2025 was the 32nd consecutive year of paying an annually increasing dividend, and highlights that reported sales increased 5%, core sales increased 2%, reported net income increased 5% to $392.8 million 32, and reported earnings per share increased 7% to $5.89 33. The company returned $485.8 million 34 to shareholders through share repurchases and dividends. Management's strategic priorities include focusing on organic growth with an added focus in high growth regions, focusing on talent and leadership, excellence in core business functions of innovate, produce and sell, focusing on managing fixed costs and improving return on invested capital, and pursuing acquisitions and partnerships. For the first quarter of 2026, management expects earnings per share, excluding any restructuring expenses, changes in the fair value of equity investments and acquisition-related costs, to be in the range of $1.13 to $1.21 35 based on an effective tax rate range of 21% to 23% 36.
For the fiscal year ended December 31, 2025, total net sales were $3,777,181 thousand 37 compared to $3,582,890 thousand 38 in 2024. Net income attributable to AptarGroup, Inc. was $392,789 thousand 39 in 2025 versus $374,541 thousand 40 in 2024. Diluted earnings per share were $5.89 41 in 2025 compared to $5.53 42 in 2024. Operating income was $501,038 thousand 43 in 2025 versus $496,497 thousand 44 in 2024. The reported effective tax rate was 20.1% 45 in 2025 compared to 20.3% 46 in 2024. Net cash provided by operations was $569,999 thousand 47 in 2025 versus $643,413 thousand 48 in 2024. Free cash flow was $302,888 thousand 49 in 2025 compared to $366,932 thousand 50 in 2024. Total debt was $1,482,964 thousand 51 at December 31, 2025 versus $1,026,351 thousand 52 at December 31, 2024. Cash and equivalents were $402,424 thousand 53 at December 31, 2025 compared to $223,844 thousand 54 at December 31, 2024. The Net Debt to Net Capital ratio was 28.6% 55 at December 31, 2025 versus 24.4% 56 at December 31, 2024. Significant one-time items in 2025 included a gain from remeasurement of equity method investment of $26,518 thousand 57, restructuring initiatives of $9,837 thousand 58, and other special items of $8,360 thousand 59 related to non-ordinary-course litigation. For segment performance, the Pharma segment reported net sales of $1,737,481 thousand 60 and Adjusted EBITDA of $607,646 thousand 61; the Beauty segment reported net sales of $1,309,437 thousand 62 and Adjusted EBITDA of $158,771 thousand 63; and the Closures segment reported net sales of $730,263 thousand 64 and Adjusted EBITDA of $116,477 thousand 65.
The company faces significant risks from geopolitical conditions, including trade disputes and tariffs, which in 2025 increased the cost of certain raw materials and components and have the potential to disrupt the global supply chain. The company has approximately $1.08 billion 31 in recorded goodwill at December 31, 2025, and changes in future business conditions could cause this asset to become impaired, requiring write-downs that would reduce operating income. The company is subject to a number of lawsuits and claims, including patent infringement actions filed by Nemera in France and Germany relating to certain ophthalmic products, and an antitrust lawsuit filed by ARS Pharmaceuticals Operations, Inc. alleging violations of U.S. competition laws. Higher raw material costs and other inputs, particularly plastic resin, rubber, metal, and energy costs, are volatile and susceptible to rapid changes due to factors beyond control, and the company may not be able to offset these higher costs with price increases. The company has foreign currency translation and transaction risks, with primary exposure to the euro, and a strengthening U.S. dollar has a dilutive effect on financial statements.
Analysis on 9/27/2026
